Guardant Health avoided trebled damages in a patent infringement dispute tied to TwinStrand Biosciences and University of Washington duplex consensus sequencing IP. In a US District Court ruling, the court denied Guardant’s motion for judgment as a matter of law or a new trial and awarded TwinStrand ongoing royalties at a 6% rate, along with supplemental damages for infringing sales during the period specified by the case record.